627 results on '"Gruel, Y"'
Search Results
2. Diagnóstico y tratamiento de las trombocitopenias inducidas por la heparina
3. Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021): From the French working group on perioperative haemostasis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French society of anaesthesia and intensive care (SFAR)
4. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia
5. Hemostasia: fisiología y principales pruebas de exploración
6. Diagnosis and management of heparin-induced thrombocytopenia
7. Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism
8. Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR)
9. Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR)
10. Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR)
11. PB0348 Can 5B9, a Monoclonal Antibody to PF4/H, be Useful in Improving the Performance of the Asserachrom HPIA Test for the Diagnosis of HIT?
12. OC 42.4 Usefulness of 1E12, a Monoclonal Anti-Platelet Factor 4 Antibody to Improve Diagnosis of Vaccine-Induced Immune Thrombotic Thrombocytopenia
13. PB0797 Comparison of Platelet Activation between Established and Novel FCγRIIA Ligands
14. PB0344 The Impact of Spleen Tyrosine Kinase-Inhibition on 5B9 HIT Antibody-Induced Procoagulant Platelet Formation
15. 5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin‐induced thrombocytopenia antibodies
16. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
17. Recommandations sur la gestion de l'anticoagulation dans un contexte d'urgence.
18. Accidents vasculaires cérébraux ischémiques artériels néonatals : synthèse des recommandations
19. Risque thrombotique et chirurgie orthopédique chez l'enfant
20. Anti‐A2 and anti‐A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A
21. Les thrombocytopénies induites par l’héparine : données récentes
22. VEGF, facteur tissulaire, marqueurs de la coagulation et de la fibrinolyse dans les malformations vasculaires à flux lent : étude prospective et impact du sirolimus
23. Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d’intérêt en Hémostase Périopératoire (GIHP) - mars 2013
24. Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study
25. The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII
26. Accident vasculaire cérébral ischémique du nouveau-né : quels facteurs biologiques de risque thrombotique rechercher et quelles conséquences en pratique ?
27. Post‐operative platelet count profile: the most reliable tool for identifying patients with true heparin‐induced thrombocypenia after cardiac surgery
28. Particularités de l’hémostase chez le nouveau-né et implications en pathologie
29. Comparative in vitro evaluation of thrombin generation assay (TGA) after spiking fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) to samples from patients undergoing orthotopic liver transplantation (OLT): OR428
30. Plasma-derived factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A: report of the FranceCoag Network: OR143
31. Variable impact of normal IgG subclasses on heparindependent platelet aggregation induced by a HIT monoclonal antibody according to FcγRIIa H131R polymorphism: PI05
32. Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021)
33. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia
34. Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin‐induced thrombocytopenia
35. Improved PCR method for amplification of GC-rich DNA sequences
36. Impact of polymorphisms affecting the ACP1 gene on levels of antibodies against platelet factor 4–heparin complexes
37. Detection and measurement of anti-IL8 IgG antibodies in cardiac surgery patients and heparin-induced thrombocytopenia using a multiplexed fluorimetric assay: PA 3.08–3
38. Prospective evaluation of a rapid and IgG specific nanoparticle-based lateral flow immunoassay (Stic Expert HIT®) for the diagnosis of heparin-induced thrombocytopenia: PA 3.08–4
39. Impact of polymorphisms affecting ACP1, which codes for a protein tyrosine phosphatase, on levels of antibodies to platelet factor 4/heparin complexes: OC 21.3
40. Use of Haemate® P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study
41. Clinical characteristics of patients with von Willebrand disease included in the Francecoag network: PO-MO-237
42. Clotting factor consumption in hemophilia A and B according to patientsʼ characteristics: Results from the FranceCoag Network: PO-TU-026
43. Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay
44. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis
45. Diagnosis and management of heparin-induced thrombocytopenia
46. Heparin-induced thrombocytopenia: is there a genetic predisposition?: No.26
47. Surgery and transfusions are associated with higher inhibitor incidence in 104 PUPs with severe haemophilia A: 17P32
48. A weekend workshop for haemophilia care: 12P10
49. Tumor expression of alternatively spliced tissue factor is a prognostic marker in non-small cell lung cancer
50. The risk of heparin-induced thrombocytopenia is increased in patients homozygous for the GNB3 825T allele: OC-TH-022
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.